Canoe Financial LP Raises Stock Position in Icon Plc $ICLR

Canoe Financial LP boosted its stake in shares of Icon Plc (NASDAQ:ICLR) by 2.1% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 197,970 shares of the medical research company’s stock after acquiring an additional 4,119 shares during the period. Canoe Financial LP owned about 0.25% of Icon worth $34,645,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Artisan Partners Limited Partnership raised its position in shares of Icon by 67.4% during the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock worth $1,045,039,000 after purchasing an additional 2,893,946 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Icon by 21.0% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,752,008 shares of the medical research company’s stock worth $545,730,000 after buying an additional 650,379 shares during the last quarter. Invesco Ltd. increased its stake in Icon by 3.3% during the 2nd quarter. Invesco Ltd. now owns 3,085,993 shares of the medical research company’s stock worth $448,858,000 after buying an additional 98,032 shares in the last quarter. Ninety One UK Ltd raised its holdings in shares of Icon by 2.6% during the second quarter. Ninety One UK Ltd now owns 2,993,652 shares of the medical research company’s stock valued at $435,427,000 after acquiring an additional 75,465 shares during the last quarter. Finally, Ruane Cunniff & Goldfarb L.P. lifted its position in shares of Icon by 36.2% in the second quarter. Ruane Cunniff & Goldfarb L.P. now owns 1,708,183 shares of the medical research company’s stock valued at $248,455,000 after acquiring an additional 453,833 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Ratings Changes

ICLR has been the subject of several research reports. Leerink Partners set a $220.00 price target on Icon in a research report on Thursday, October 23rd. Jefferies Financial Group lowered shares of Icon from a “buy” rating to a “hold” rating and dropped their target price for the stock from $220.00 to $175.00 in a report on Tuesday, September 9th. Robert W. Baird set a $220.00 target price on shares of Icon in a research report on Friday, October 24th. Zacks Research upgraded shares of Icon from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 25th. Finally, Rothschild & Co Redburn raised shares of Icon from a “neutral” rating to a “buy” rating and upped their price objective for the company from $184.00 to $236.00 in a research note on Wednesday, September 3rd. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $205.31.

Icon Stock Up 0.3%

NASDAQ ICLR opened at $183.64 on Friday. The business’s fifty day simple moving average is $175.41 and its 200-day simple moving average is $169.41. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The firm has a market cap of $14.83 billion, a PE ratio of 24.85, a P/E/G ratio of 3.40 and a beta of 1.25. Icon Plc has a 52 week low of $125.10 and a 52 week high of $228.29.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.